BofA raised the firm’s price target on Alnylam (ALNY) to $328 from $325 and keeps a Buy rating on the shares. The firm updated models in smid-cap biotech as part of a Q1 earnings preview.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam Pharma’s Promising Launch and Strategic Positioning Drive Buy Rating
- Alnylam price target lowered to $268 from $284 at Morgan Stanley
- Alnylam Pharma’s Strong Market Position and Growth Potential Justify Buy Rating
- Seeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy
- Hold Rating on Alnylam Pharma’s Qfitlia Amid FDA Approval and Market Challenges
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue